Loading
Cases by country, the UK and NHS pathway and other country lenses, the expert centres with trials on record, and the centres named on this cancer's subtypes.
Site: Trachea, bronchus and lung (shared total; subtype split not reported). World: 2,480,675 new cases a year.
| # | Country | New cases | Incidence ASR |
|---|---|---|---|
| 1 | China | 1,060,584 | |
| 2 | United States of America | 226,033 | |
| 3 | Japan | 136,723 | |
| 4 | India | 81,748 | |
| 5 | Russian Federation | 70,362 | |
| 6 | Germany | 62,025 | |
| 7 | United Kingdom | 50,700 | |
| 8 | France (metropolitan) | 49,613 | |
| 9 | Brazil | 44,213 | |
| 10 | Italy | 43,808 |
GLOBOCAN does not split lung cancer by histology. NSCLC is roughly 85% of lung cancer; figures are for all lung cancer.
Country-level death counts mix every stage, subtype and year of diagnosis, and reflect access to screening and treatment as much as the disease. Survival differs by stage, subtype and year; the cancer page above leads with what can be done.
| # | Country | New cases | Deaths |
|---|---|---|---|
| 1 | China | 1,060,584 | 733,291 |
| 2 | United States of America | 226,033 | 127,653 |
| 3 | Japan | 136,723 | 83,243 |
| 4 | India | 81,748 | 75,031 |
| 5 | Russian Federation | 70,362 | 51,887 |
| 6 | Germany | 62,025 | 47,731 |
| 7 | United Kingdom | 50,700 | 35,394 |
| 8 | France (metropolitan) | 49,613 | 36,876 |
| 9 | Brazil | 44,213 | 38,292 |
| 10 | Italy | 43,808 | 35,668 |
World: 2,480,675 new cases and 1,817,469 deaths a year (GLOBOCAN 2022).
Waiting-time standards, the specialist centres, what NICE and the SMC fund by line of treatment, the National Genomic Test Directory codes, the trials open in the UK and the differences across the four nations.
New York · cancer center | United States | 0 | 5,120 | 95,936 | #1 | ||
Houston · cancer center | United States | 0 | 6,742 | 95,559 | #2 | ||
| South Korea | none recorded | 0 | 1,319 | 17,459 | #3 | ||
Rochester, MN · hospital | United States | 0 | 4,572 | 48,202 | #5 | ||
Villejuif · cancer center | France | none recorded | 0 | 1,862 | 31,707 | #6 | |
London · cancer center | United Kingdom | none recorded | 0 | 1,030 | 18,019 | #7 | |
| South Korea | none recorded | 0 | 1,612 | 26,269 | #8 | ||
Baltimore · cancer center | United States | 0 | 2,962 | 42,161 | #10 | ||
Berlin · university | Germany | none recorded | 0 | 1,567 | 18,047 | #12 | |
Tokyo · government | Japan | none recorded | 1 | 1,599 | 21,937 | none recorded | #13 |
| United States | 0 | 4,333 | 74,896 | none recorded | #15 | ||
| United States | 0 | 3,584 | 55,693 | #16 | |||
Heidelberg · cancer center | Germany | none recorded | 0 | 3,473 | 46,508 | #18 | |
Cleveland · hospital | United States | 0 | 2,275 | 29,951 | #20 | ||
Paris · cancer center | France | none recorded | 0 | 1,044 | 15,238 | #21 |
These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with Non-small-cell lung cancer but is thinly recorded here will look small.
Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.
30 centres are named on one of the types below rather than on Non-small-cell lung cancer itself. Grouped by the type that holds them; the full table for each sits on that type's page.